文献速递骨质疏松与钙磷/甲状旁腺

他汀不影响特立帕肽对老年女性的骨合成代谢

Statins Do Not Affect Bone Anabolism in Older Women Treated With Teriparatide.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

结果显示他汀使用者腰椎骨密度显著增加且股骨颈有改善趋势,非使用者腰椎骨密度也增加但股骨颈无显著变化;他汀使用者I型胶原C端肽显著低于非使用者。结论认为他汀不损害特立帕肽的骨密度增益,并提供额外抗骨吸收获益。

要点

  • 他汀不影响特立帕肽对绝经后严重骨质疏松女性的腰椎骨密度增益。
  • 他汀使用者在特立帕肽治疗期间I型胶原C端肽显著低于非使用者。
  • 碱性磷酸酶和骨钙素在两组间无显著差异。

核心结论

  • 他汀使用不损害rhPTH增加绝经后严重骨质疏松女性骨密度的合成代谢效能,并提供额外抗骨吸收获益。

主要发现

  • 他汀使用者腰椎骨密度从0.71 ± 0.16增至0.79 ± 0.14 g/cm²(P = .01),股骨颈从0.53 ± 0.24至0.62 ± 0.12 g/cm²呈改善趋势(P = .07)。
  • 非使用者腰椎骨密度从0.70 ± 0.10增至0.77 ± 0.11 g/cm²(P = .001),股骨颈从0.60 ± 0.11至0.58 ± 0.15 g/cm²无显著变化(P = .5)。
  • 观察结束时他汀使用者I型胶原C端肽显著低于非使用者(0.37 ± 0.29 vs 0.66 ± 0.47 ng/mL,P = .007)。
  • 碱性磷酸酶和骨钙素在整个观察期间组间无显著差异。

临床怎么用

  • 在接受特立帕肽治疗的绝经后严重骨质疏松女性中可继续使用他汀,无需担心削弱骨密度增益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Teriparatide [rhPTH (1-34)] is an established anabolic agent for the treatment of severe osteoporosis. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, have demonstrated antiresorptive properties, but their impact on the anabolic efficacy of rhPTH remains unclear. OBJECTIVE: To evaluate whether concurrent statin therapy influences changes in bone mineral density (BMD) and bone turnover markers in women receiving rhPTH. METHODS: This retrospective cohort study included 104 postmenopausal women with severe osteoporosis who completed 24 months of daily rhPTH (20 mcg subcutaneously) and biweekly cholecalciferol (25 000 IU). Patients were stratified by statin use. BMD at the lumbar spine and femoral neck was assessed at baseline and study completion. Bone turnover markers-alkaline phosphatase, osteocalcin, and C-terminal telopeptide of type I collagen-were measured every 6 months. RESULTS: Thirty patients were statin users and 74 were nonusers. Statin users experienced lumbar spine BMD gain from 0.71 ± 0.16 to 0.79 ± 0.14 g/cm² (P = .01) and a trend toward femoral neck improvement from 0.53 ± 0.24 to 0.62 ± 0.12 g/cm² (P = .07). Nonusers also showed a lumbar spine BMD rise from 0.70 ± 0.10 to 0.77 ± 0.11 g/cm² (P = .001), with no significant femoral neck BMD change from 0.60 ± 0.11 to 0.58 ± 0.15 g/cm² (P = .5). At the end of the observation period, C-terminal telopeptide of type I collagen levels were significantly lower in statin users compared to nonusers (0.37 ± 0.29 vs 0.66 ± 0.47 ng/mL, P = .007). Conversely, no significant intergroup differences were observed for alkaline phosphatase and osteocalcin throughout the observation period. CONCLUSION: Statin use does not impair the anabolic efficacy of rhPTH in increasing BMD in postmenopausal women with severe osteoporosis, but it provides additional antiresorptive benefits during rhPTH therapy. These findings support the continued use of statins and highlight the need for further prospective studies exploring synergistic effects.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Oliveri C, Xourafa A, Morabito N, et al. Statins Do Not Affect Bone Anabolism in Older Women Treated With Teriparatide. J Clin Endocrinol Metab. 2026. PMID: 40976592. doi:10.1210/clinem/dgaf523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。